Pilot prescription survey of antineoplastic agents: real-world data from veterinary teaching hospitals in Japan

Noriko Tanaka*, Tsuyoshi Takizawa†, Ryo Tanaka‡, Shozo Okano§, Shinji Funayama* and Toshio Iwasaki¶

*Department of Pharmaceutical Sciences, Nihon Pharmaceutical University, Saitama, Japan, †Department of Pharmaceutical Sciences, Chiba Institute of Science, Choshi, Chiba, Japan, ‡Department of Veterinary Surgery, Faculty of Veterinary Medicine, Tokyo University of Agriculture & Technology, Fuchu, Tokyo, Japan, §Department of Small Animal Surgery, Veterinary Teaching Hospital, School of Veterinary Medicine, Kitasato University, Towada, Aomori, Japan and ¶Department of Veterinary Internal Medicine, Faculty of Veterinary Medicine, Tokyo University of Agriculture & Technology, Fuchu, Tokyo, Japan

Abstract

The collection of real clinical records from veterinary practices and analysis of these records helps to establish evidence-based veterinary medicine and further improves animal health and welfare. Prior to the collection of nationwide clinical records, we downloaded the data from the digital accounting systems of two veterinary teaching hospitals in Japan, and the prescriptions of antineoplastic agents were surveyed for a 5-year period from 2009 to 2013. The ratio of the number of patients prescribed antineoplastic agents to the total number of prescriptions was <5% at both hospitals, and >80% of those patients were dogs. The overall number of prescriptions included more oral rather than injectable formations, whereas among antineoplastic agents, injectable formulations were prescribed more frequently at both hospitals. The most frequently prescribed agents were almost identical at both hospitals: platinum compounds, such as carboplatin and cisplatin (CDDP), vincristine and doxorubicin. The most frequently prescribed product combined with CDDP was doxorubicin at Hospital A. Antiemetic agents combined with CDDP included dexamethasone, ondansetron and metoclopramide, but these antiemetic agents were combined fewer than 10 times among 197 CDDP prescriptions. The prescription history, including the number of prescriptions, dosing intervals and combined medications, was provided by the survey. Although the present database consisted of data from two hospitals, our results indicate that a broad analysis can be conducted using integrated data from multiple hospitals and practices for further cohort studies.

Keywords: companion animals, electronic health records, prescription surveillance, antineoplastic agents, veterinary teaching hospital.

Introduction

Analysis of a database composed of electronic patient records enables veterinarians to establish evidence-based veterinary medicine and select cost-effective treatments, thus improving animal health and welfare. For example UK VetCompass and VetCompass Australia are nationwide big data collection platforms (O’Neill et al. 2014a, 2014b; McGreevy et al. 2017). In Japan, both in veterinary practices and even in veterinary teaching hospitals, most patient records are still stored as paper-based health records or separate data in individual medical devices without connection to hospital management systems (Tanaka 2011). However, according to a previous survey (Tanaka 2011; Miyamoto et al. 2013), account-related items are electronically stored in hospital management systems in teaching hospitals. Using these data, we conducted a prescription survey of pharmaceuticals used in one teaching hospital and revealed that 76% of all prescriptions were drugs approved for humans (Tanaka et al. 2017). The
antineoplastic agents (anticancer drugs) prescribed were all products approved for humans.

In companion animals, the incidence of age-related disorders such as malignancies, cardiovascular diseases, obesity and diabetes increases as the animal ages (Inoue et al. 2015). The life expectancy of dogs has been extended in recent years in Japan (Suda 2011), which has resulted in an increased occurrence of age-related disorders. Thus, medical products are needed that differ from those previously approved for veterinary use. Veterinary teaching hospitals in Japan are referral hospitals for primary care veterinarians. Various pharmaceuticals are used at teaching hospitals to treat older patient disorders, such as malignancies, thus promoting off-label use of pharmaceuticals intended for human use. Several prescription surveys have been conducted at veterinary hospitals in many Western countries (Cave et al. 2007; Lobo et al. 2011; Wayne et al. 2011; Hughes et al. 2012; Carmo et al. 2017; McDougall et al. 2017). Almost all these surveys targeted prescriptions of anti-infectious antibiotics and chemotherapeutics. Prescription surveys focusing on age-related disorders treated by off-label use of medicinal products for humans can provide real-world treatment evidence such as the dose, dosing schedule, combined medical products and patient information.

In this study, the prescription data of two teaching hospitals that use the same digital system were surveyed to clarify the problems caused by merging the data. Prescription of antineoplastic agents was the focus of the present survey because the incidence of malignancies increases with age (Inoue et al. 2015b) and because among diagnostic categories, neoplasia represents the most frequent cause of death for dogs (Inoue et al. 2015). To establish more appropriate protocols, a survey of prescription histories using combination therapy is useful. Because many protocols for cancer treatments involve combinations of antineoplastic agents with different mechanisms (Cannon et al. 2015; Mauldin et al. 1988; Childress et al. 2018) and because antiemetics are used to reduce nausea and vomiting caused by antineoplastic agents (de la Puente-Redondo et al. 2007; Kenward et al. 2017), the prescription history for each patient (especially for combination prescriptions) was also surveyed. This study is a pilot study to establish an appropriate survey method using digital health records to acquire real-world veterinary evidence.

**Materials and methods**

**Hospital selection criteria**

Two of 16 Japanese veterinary teaching hospitals were selected based on the results of a questionnaire for hospital management systems (Tanaka 2011). These two referral hospitals for companion animals have the same digital accounting system, which is the most widely used hospital management system in Japan. The system is supported with a remote-controlled system under a maintenance contract. Hospital A is located in the Tokyo suburbs, and Hospital B is located in the local provincial city suburbs.

**Prescription records**

According to previously described methods (Tanaka et al. 2017), electronic prescription records were downloaded from Anicom Receptor (Anicom Pafe Inc., Tokyo, Japan), a veterinary hospital management system. Each hospital council approved the download of digital records from Anicom Receptor for use in the present surveillance study. The downloaded records included the following information: item number and treatment information, including the product name, prescription date, usage, dose, patient identification number (ID number), animal species, breed, sex, body weight, age, serial number and health record number. Personal data such as the patient owners’ names, any information or ID numbers related to the owners, or the patients’ names were not downloaded. The electronic file containing the downloaded data was sent to the author with a password. Data from 1 January 2009 to 31 December 2013 were analysed in this study.

**Product information**

Among the downloaded treatment records, only medicinal products identified using the brand names were processed. The detailed method was described
previously (Tanaka et al. 2017). Briefly, according to the Japan Standard Commodity Classification (Ministry of Internal Affairs and Communications, Statistic Bureau), the pharmaceutical therapeutic category (i.e. antineoplastic agents) was recognized in this study. Antineoplastic agents with another indication category were processed after an interview with the clinicians at the hospital regarding whether the product was used to treat cancer. In this study, products not indicated for use as antineoplastic agents were excluded even though veterinarians prescribed them to treat cancer patients (e.g. non-steroidal anti-inflammatory drugs [NSAIDs]).

Data analysis

The prescription records and product name files were imported as data sets into SAS9.3 software (SAS Institute Japan Inc., Tokyo, Japan). The two data sets were match-merged by treatment, thus attaching the brand name, generic name and classification code to the prescription records. Frequency distributions from the prescription data were examined. Infusion fluids were excluded from the present analysis because these products were not always recognized as independent accounting items by veterinary medical personnel in the hospitals (personal communication).

Guidance

Because routinely collected health data were analysed in this study, RECORD guidance was used (Benchimol et al. 2015).

Results

The overall numbers of patient consultations were 10,681 and 8,424 at Hospitals A and B, respectively, during the 5-year study period (Table 1). The numbers of patients prescribed an antineoplastic agent were 377 (3.5% of all patients) and 194 (2.3% of all patients) at Hospitals A and B, respectively. More than 80% of all patients were dogs (5.3-fold and 5.2-fold more than cats at Hospitals A and B, respectively). More than 80% of the patients prescribed antineoplastic agents were also dogs (4.5-fold more than cats at both hospitals). In total, 77,017 prescriptions were noted at Hospital A, including agents against pathogenic organisms, cardiovascular agents and other agents from 19 categories; 72.9% were oral products, although 76.0% of the antineoplastic agents prescribed were injectable (Table 2). In total, 43,806 prescriptions were noted at Hospital B, 55.2% of which were oral products, whereas 67.9% of antineoplastic agent prescriptions were injectable. All antineoplastic agents prescribed were products approved for human use. Any available veterinary antineoplastic agent was prescribed at either hospital during the study period, although toceranib is marketed in the United States and masitinib is in the EU. Figure 1 shows the annual changes in the number of prescribed antineoplastic agents at Hospitals A and B. No specific tendencies, such as an increase or decrease in prescription numbers, were observed. The number of prescriptions for each product is shown in Table 3. At Hospital A, the platinum compounds carboplatin and cisplatin (CDDP) were the most frequently prescribed agents, with 449 and 197 prescriptions, respectively (up to 30.7% of the total), followed by vincristine with 322 (15.3%) prescriptions and doxorubicin with 253 (12.0%) prescriptions. Both injectable and oral formulations of cyclophosphamide were used (105 and 305, respectively; up to 19.7%). At Hospital B, vincristine was the most frequently prescribed agent with 144 (16.6%) prescriptions, followed by cyclophosphamide with 99 injectable and 52 oral (up to 17.4%) prescriptions, oral chlorambucil with 90 (10.4%) prescriptions, platinum compounds including carboplatin with 72 prescriptions and CDDP with 9 prescriptions (together accounting for 9.3% of the total) and doxorubicin with 68 (7.8%) prescriptions. Nimustine was prescribed only at Hospital A, whereas procarbazine, methotrexate, bleomycin, etoposide, picibanil, lentinan and tretinoin were prescribed only at Hospital B. Because the number of patients prescribed antineoplastic agents was 1.8-fold higher at Hospital A than that at Hospital B, the number of prescriptions for each product was higher at Hospital A than that at Hospital B with the exception of chlorambucil. CDDP was used much less
frequently at Hospital B versus Hospital A. Among the products shown in Table 3, the annual change in the number of prescriptions for five products (carboplatin, CDDP, vincristine, doxorubicin and cyclophosphamide) is shown in Fig. 2. At Hospital A, the number of carboplatin prescriptions decreased from 2012, whereas the number of CDDP prescriptions markedly increased: a 14.5-fold increase from 2009 to 2013. At both hospitals, carboplatin was prescribed for both dogs and cats, but CDDP was only prescribed for dogs. The prescription times and intervals of CDDP are shown in Table 4. The mean numbers of prescriptions were 5.0 and 2.3 at Hospitals A and B, respectively. Combined prescriptions were analysed for 32 CDDP-prescribed dogs, and CDDP was prescribed a total of 197 times to the dogs at Hospital A. Among these 197 CDDP prescriptions, doxorubicin was additionally prescribed 50 times, and oral imatinib was prescribed two times. Injectable furosemide, a diuretic agent, was used in combination with CDDP two times. Antiemetics were used fewer than 10 of 197 times in combination with CDDP and comprised nine prescriptions for oral dexamethasone, two prescriptions for injectable ondansetron and one prescription for injectable metoclopramide. In addition to antiemetics, the gastrointestinal agent famotidine was prescribed eight times in combination with CDDP. The mean number of prescriptions for carboplatin in each individual patient was 5.0 ± 3.8, and the median number was 4.0 at Hospital A, the values of which were almost the same as those for CDDP prescriptions from 1 January 2009 to 31 December 2013.

Among several antineoplastic kinase inhibitors, only imatinib was prescribed at both hospitals; it was prescribed 49 and 43 times at Hospitals A and B, respectively. The prescription histories for seven and five dogs receiving imatinib were examined at Hospitals A and B, respectively. A female miniature dachshund had the longest duration (44 hospital visits and 25 imatinib prescriptions at Hospital A). Twenty-five ursodeoxycholic acid prescriptions, 24 famotidine prescriptions and 20 prednisolone prescriptions were combined with the 25 imatinib prescriptions. These three drugs (ursodeoxycholic acid, prednisolone and imatinib) were preferentially combined for other patients who were prescribed imatinib at Hospital A (data not shown). No prescription record for toceranib, a veterinary antineoplastic agent, was found at either hospital during our evaluation period.

### Discussion

Several surveillance studies have been conducted using electronic records, paper prescription records or Internet databases (Cave et al. 2007; Lobo et al. 2011; Radford et al. 2011; Wayne et al. 2011; Hughes et al. 2012; Kvaale et al. 2013; Carmo et al. 2017; McDougall et al. 2017). Most of these studies focused on the use of antimicrobial agents. Among them, Cave et al. (2007) examined the use of cytotoxic antineoplastic agents using a postal survey of UK veterinary practices. This study is the only report to analyse antineoplastic agents using medical treatment records. The ratios of patients with an antineoplastic agent prescription to the total number of patients were 3.5% and 2.3% at Hospitals A and B, respectively. However, the preferred formulation of antineoplastic agents was different from that of the overall patient group. This difference was observed
because the overall group of patients mainly comprised patients prescribed agents against pathogenic organisms, cardiovascular agents, or agents affecting digestive organs as reported in a previous study (Tanaka et al. 2017), whereas antineoplastic agents were prescribed for <5% of the total population. Although oral products were preferably prescribed for the abovementioned categories (e.g. agents against pathogenic organisms), an injectable formulation was preferably prescribed for antineoplastic agents because the chemotherapeutic agents available for human patients with malignancy were injectable formulations before the development of oral kinase inhibitors.

In the study by Cave et al. (2007), the most widely prescribed antineoplastic agents in the UK practices were cyclophosphamide (65.4%) and vincristine (63.5%). Platinum-based agents such as CDDP and carboplatin composed 8.3% of the prescriptions. In this study, cyclophosphamide and vincristine were also widely used products at both hospitals, but they were used less frequently compared with data in the UK: 19.7% and 17.4% for cyclophosphamide and 15.3% and 16.6% for vincristine at Hospitals A and B, respectively. However, platinum-based agents were prescribed more frequently in this study (30.7% and 9.3% at Hospitals A and B, respectively) than in the UK according to a survey report in 2007 (8.3%). The median frequency of prescriptions ranged from once a month to once every 3 months in the UK (Cave et al. 2007). The median frequency of CDDP prescription was once every 4 weeks at Hospital A

Table 2. Numbers of oral and injectable product prescriptions

| Hospital | Prescribed category | Number of prescriptions (%)* |
|----------|--------------------|-----------------------------|
|          |                    | Total | Injectable | Oral       |
| A        | All                | 77017 (100%) | 20834 (27.1%) | 56183 (72.9%) |
|          | Antineoplastic agents | 2103 (100%) | 1598 (76.0%) | 505 (24.0%) |
| B        | All                | 43806 (100%) | 19638 (44.8%) | 24168 (55.2%) |
|          | Antineoplastic agents | 590 (100%) | 590 (67.9%) | 279 (32.1%) |

*The ratio of the instances to the total number of prescriptions in each category is in parentheses.

Fig. 1. Annual changes in the numbers of antineoplastic agent prescriptions during the 5-year study period. The open square indicates Hospital A, located in a Tokyo suburb; the closed square indicates Hospital B, located in the local provincial city suburbs. Each column on the left indicates the number of prescriptions for injectable formulations in a given year, and each column on the right indicates the number of prescriptions for oral formulations in a given year. No specific tendency was observed.
Table 3. Numbers of prescriptions of antineoplastic agents

| Oncology drug category and subcategory | Active ingredient | Hospital A Injectable | Hospital A Oral | Hospital B Injectable | Hospital B Oral |
|---------------------------------------|-------------------|-----------------------|----------------|-----------------------|----------------|
| Alkylating agents                      | Mustard compounds | Cyclophosphamide      | 105            | 309                   | 99            |
|                                       |                   | Melphalan             | na*            | 49                    | na            |
|                                       |                   | Chlorambucil          | na             | 49                    | na            |
| Nitrosoureas                           | Nimustine         | na                    | 58             | na                    | 0             |
|                                       | Lomustine         | na                    | na             | 49                    | na            |
| Others                                | L-asparaginase    | na                    | 66             | na                    | 63            |
|                                       | Procarbazine      | na                    | na             | 0                     | na            |
| Antimetabolite                         | Anti-foxic        | Methotrexate          | 0              | na                    | 7             |
|                                       | Anti-pyrimidines  | Cytarabine            | 20             | na                    | 34            |
| Antibiotics                            | Anthrycycines     | Doxorubicin           | 253            | na                    | 68            |
|                                       |                   | Mitoxantrone          | 2              | na                    | 13            |
|                                       | Bleomycin         | na                    | 0              | na                    | 5             |
|                                       | Actinomycin D     | na                    | 28             | na                    | 19            |
| Anti-microtubules                      | Vinca alkaloids   | Vincristine           | 322            | na                    | 144           |
|                                       | Vinblastine       | 71                    | na             | 36                    | na            |
| Platinum                              | Cisplatin         | 197                   | na             | 9                     | na            |
|                                       | Carboplatin       | 449                   | NA             | 72                    | na            |
| Topoisomerase inhibitor               | Etoposide         | na                    | 0              | na                    | 8             |
| Kinase inhibitor                       | Imatinib          | na                    | 49             | na                    | 43            |
| Nonspecific Immuno-potentiator         | Picibanil         | 0                     | na             | 3                     | na            |
|                                       | Lentinan          | 0                     | na             | 4                     | na            |
| Others                                | Tretinoin         | 0                     | na             | 19                    | na            |
| Total                                 |                   | 1598                  | 506            | 590                   | 279           |

*na, not available.

Fig. 2. Annual changes in the number of prescriptions for frequently prescribed antineoplastic agents. The left figure shows the number of prescriptions at Hospital A, and the right figure shows the number of prescriptions at Hospital B. Each column indicates the number of prescriptions for each product in each year. Cyclophosphamide data include oral and injectable formulations. At Hospital A, the number of carboplatin prescriptions decreased from 2012, whereas the number of CDDP prescriptions increased.

© 2019 The Authors Veterinary Medicine and Science Published by John Wiley & Sons Ltd
Veterinary Medicine and Science (2019), 5, pp. 297–306
and once every 2 weeks at Hospital B. These discrepancies may be due to the country difference or differences between practices and referral hospitals. Big data analysis may allow evaluation of the reason for these differences. Combination protocols involving a platinum compound and doxorubicin have also been reported and are widely used to treat canine osteosarcoma; one such protocol is the CARBO-DOX6 protocol (Mauldin et al. 1988; Selmic et al. 2014). The use of combinations of antineoplastic agents with different mechanisms as well as antiemetics was also surveyed in this study. As shown in Fig. 2, carboplatin prescriptions decreased from 2012, whereas CDDP prescriptions increased at Hospital A. Carboplatin was switched to CDDP because of the prices of the two products, with CDDP as the less expensive agent (personal communication). Doxorubicin was the product combined most frequently with CDDP. Treatment-related adverse events associated with CDDP were somewhat different from those associated with carboplatin, such as the contraindication in cats because of dose-related severe pulmonary toxicities, renal impairment or myelosuppression (Plumb 2015). Carboplatin is less nephrotoxic and less emetic than CDDP in animals as well as in humans (Rose & Schurig 1985; Multinational Association of Supportive Care in Cancer, 2016). In addition to the general adverse events associated with chemotherapeutics, such as myelosuppression, CDDP dosing requires hydration to inhibit renal impairment progression (Plumb 2015), and the combined use of several antiemetics to control emesis is also recommended in veterinary medicine (de la Puente-Redondo et al. 2007; Rau et al. 2010; Kenward et al. 2017). A worldwide online survey by the American Society of Clinical Oncology showed that the development of antiemetics was voted as one of the ‘Top 5 Advances in 50 Years of Modern Oncology’ (American Society of Clinical Oncology, 2014). The use of antiemetics improves patients’ quality of life and allows them to tolerate an adequate dose intensity of antineoplastic agents (Multinational Association of Supportive Care in Cancer, 2016). In this study, antiemetics were infrequently combined with 197 CDDP prescriptions, with only two ondansetron injection prescriptions (1%) and one metoclopramide injection prescription (0.5%). Oral dexamethasone was prescribed in combination with CDDP nine times (4.6%), but the prescription purpose of dexamethasone could not be determined (personal communication). Other than antiemetics, famotidine was used eight times.

A prescription history survey can be useful to establish a standard therapy protocol, indicating the importance of a combination survey. The present survey shows that there was no prescription data for the antineoplastic product approved for veterinary use, toceranib. The supply of toceranib to the hospitals was restricted during the study period; since then, however, the product has become available for prescription at these hospitals (personal communication). Analysis of the use of antineoplastic products approved for veterinary use will become possible in the near future. Imatinib was the only kinase inhibitor prescribed at both hospitals. KIT tyrosine kinase is the target protein for imatinib as well as toceranib, an antineoplastic product approved for veterinary use (Heinrich et al. 2000; Pryer et al. 2003; London et al. 2012). The prescription history of the dog with the longest term consisted of 44 hospital visits and 25 imatinib prescriptions at Hospital A. Because consecutive treatments are essential for kinase inhibitors, this long treatment experience with imatinib revealed that the patient tolerated the drug well. The data can be referenced for the future use of newly marketed antineoplastic products approved for veterinary use, such as toceranib and masitinib, which are similar to imatinib. In the present survey, a prescription history survey was conducted for each

| Hospital | Total number of prescriptions | The number of CDDP-prescribed animals | The prescription number per patient |
|----------|-------------------------------|--------------------------------------|-----------------------------------|
|          |                               | Dogs | Cats | Mean ± SD* | Median (95% CI†) |
| A        | 197                           | 32   | 0    | 5.0 ± 4.4  | 4 (2–5)          |
| B        | 9                             | 4    | 0    | 2.3 ± 0.4  | 2 (–)            |

*SD, standard deviation. †CI, confidence interval.

Table 4. Prescription analysis for cisplatin (CDDP)
individual patient. A prescription history survey combined with additional haematological or biomarker examination data can provide real-world treatment evidence and facilitate the development of standard protocols in veterinary medicine.

The present database included data from two hospitals, and the same analytical methods were applied for merged data from the two hospitals without problems, indicating that a broad analysis can be conducted using integrated data from multiple hospitals and practices. VetCompass Australia, a nationwide big data collection system for veterinary science, was started in 2017 (McGreevey et al. 2017); likewise, VetCompass has been running in the UK for 7 years (O’Neill et al. 2014a, 2014b). Such a nationwide data collection system based on real veterinary health records can promote cohort studies and health surveillance studies.

Acknowledgements
The authors thank Dr. Tatsuro Irimura, Juntendo University for his useful advice and Dr. Kanki Komiyama, Director of the Kitasato Research Centre for Environmental Science, for his special support. The authors also thank Ms. N. Mitsui for providing helpful coding advice and Ms. U. Fukushima, Ms. Y. Shigemori and Mr. S. Kanbara, members of Dr. Tanaka’s Lab at the Chiba Institute of Science, for their contributions in providing a code number and generic name for each product. Downloading of data from the electronic accounting system and the deletion of personal information from the data were conducted by Anicom Pafe, Inc., Tokyo: the authors express special thanks to the contributors in Anicom Pafe, Inc.

Source of funding
This study was partially funded by Meiji Seika Pharma Co. Ltd., Tokyo.

Conflict of interest
The authors declare no conflict of interest.

Ethical statement
The authors confirm that the ethical policies of the journal, as noted on the journal’s author guidelines page.

Contributions
All authors agree to their contribution as shown below. The corresponding author, N. Tanaka, keeps their statements. All authors have read and approved the final manuscript.

N. Tanaka: Planned and supervised the research project, performed the research and wrote the paper.

T. Takizawa: Performed the statistical analysis and handled the SAS software.

R. Tanaka: Arranged to download data from the hospital system and reviewed the results and the paper.

S. Okano: Arranged to download data from the hospital system and reviewed the results and the paper.

S. Funayama: Supported the research progress, arranged necessary facilities and reviewed the paper.

T. Iwasaki: Arranged to download data from the hospital system and reviewed the results and the paper.

References
American Society of Clinical Oncology (ASCO). 2014. ASCO in Action. Available at: https://www.asco.org/advocacy-policy/asco-in-action/votes-are-top-5-advances-50-years-modern-oncology (Accessed 20 June 2018).

Benchimol E.I., Smeeth L., Guttmann A., Harron K., Moher D., Petersen I. et al.; R.E.C.O.R.D. Working Committee. (2015) The REPorting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLoS Medicine 12, e1001885. https://doi.org/10.1371.

Cannon C., Borgatti A., Henson M. & Husbands B. (2015) Evaluation of a combination chemotherapy protocol including lomustine and doxorubicin in canine histiocytic sarcoma. Journal of Small Animal Practice 56, 425–429.

Carmo L.P., Schüpbach-Regula G., Müntener C., Chevance A., Moulin G. & Magouras I. (2017) Approaches for quantifying antimicrobial consumption per animal species
based on national sales data: a Swiss example, 2006 to 2013. Eurosurveillance Weekly 22, 29–39.

Cave T.A., Norman P. & Mellor D. (2007) Cytotoxic drug use in treatment of dogs and cats with cancer by UK veterinary practices (2003 to 2004). Journal of Small Animal Practice 48, 371–377.

Childress M.O., Ramos-Vara J.A. & Ruple A. (2018) Retrospective analysis of factors affecting clinical outcome following CHOP-based chemotherapy in dogs with primary nodal diffuse large B-cell lymphoma. Veterinary and Comparative Oncology 16, E159–E168.

Heinrich M.C., Griffith D.J., Druker B.J., Wait C.L., Ott K.A. & Zigler A.J. (2000) Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96, 925–932.

Hughes L.A., Williams N., Clegg P., Callaby R., Nuttall T., Coyne K. et al. (2012) Cross-sectional survey of antimicrobial prescribing patterns in UK small animal veterinary practice. Preventive Veterinary Medicine 104, 309–316.

Inoue M., Hasegawa A., Hosoi Y. & Sugira K. (2015) Breed, gender and age pattern of diagnosis for veterinary care in insured dogs in Japan during fiscal year 2010. Preventive Veterinary Medicine 119, 54–60.

Inoue M., Hasegawa A., Hosoi Y. & Sugira K. (2015b) A current life table and causes of death for insured dogs in Japan. Preventive Veterinary Medicine 120, 210–218.

Kenward H., Elliott J., Lee T. & Pelligand L. (2017) Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study. BMC Veterinary Research 13, 244.

Kvaale M.K., Grave K., Kristoffersen A.B. & Norstrom M. (2013) The prescription rate of antibacterial agents in dogs in Norway - geographical patterns and trends during the period 2004-2008. Journal of Veterinary Pharmacology and Therapeutics 36, 285–291.

Lobo M., Diaz M.J., Garcia J. & Frejo M.T. (2011) Pilot study about prescription in exceptional situations. Use of drugs for human in veterinary medicine. Revista Oficial de la AsociaciónVeterinaria Española de Especialistas en Pequeños Animales 31, 143–149.

London C., Mathie T., Stingle N., Clifford C., Haney S., Klein M.K. et al. (2012) Preliminary evidence for biologic activity of toceranib phosphate (Palladia®) in solid tumours. Veterinary and Comparative Oncology 10, 194–205.

Mauldin G.N., Matus R.E., Withrow S.J. & Patnaik A.K. (1988) Canine osteosarcoma. Treatment by amputation versus amputation and adjuvant chemotherapy using doxorubicin and cisplatin. Journal of Veterinary Internal Medicine 2, 177–180.

McDougall S., Compton C. & Botha N. (2017) Factors influencing antimicrobial prescribing by veterinarians and usage by dairy farmers in New Zealand. New Zealand Veterinary Journal 65, 84–92.

McGreevy P., Thomson P., Dhand N., Raubenheimer D., Masters S., Mansfield C. et al. (2017) VetCompass Australia: a national big data collection system for veterinary science. Animals 7, 74.

Miyamoto N., Iwasaki T. & Tanaka N. (2013) Survey of medicines used in a veterinary hospital. Chiba Institute of Science 6, 93–97.

Multinational Association of Supportive Care in Cancer (MASCC). (2016) MASCC Antiemetic Guidelines. Available at: http://www.mascc.org/antiemetic-guidelines (Accessed 20 June 2018).

O’Neill D.G., Church D.B., McGreevy P.D., Thomson P.C. & Brodbelt D.C. (2014a) Prevalence of disorders recorded in dogs attending primary-care veterinary practices in England. PLoS ONE 9, e90501. https://doi.org/10.1371.

O’Neill D.G., Church D.B., McGreevy P.D., Thomson P.C. & Brodbelt D.C. (2014b) Approaches to canine health surveillance. Canine Genetics and Epidemiology 1, 1. https://doi.org/10.1186/2052-6687-1-2.

Plumb D.C. (ed) (2015) Veterinary Drug Handbook, 8th edn, pp 228–230. Wiley-Blacwell; Ames.

Pryer N.K., Lee L.B., Zadovaskaya R., Yu X., Sukbuntheng J., Cherrington J.M. & London C.A. (2003) Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors. Clinical Cancer Research 9, 5729–5734.

de la Puente-Redondo V.A., Tilt N., Rowan T.G. & Clemence R.G. (2007) Efficacy of maropitant for treatment and prevention of emesis caused by intravenous infusion of cisplatin in dogs. American Journal of Veterinary Research 68, 48–56.

Radford A.D., Noble P.J., Coyne K.P., Gaskell R.M., Jones P.H., Bryan J.G.E. et al. (2011) Antibacterial prescribing patterns in small animal veterinary practice identified via SAVSNET: the small animal veterinary surveillance network. Veterinary Record 169, 310.

Rau S.E., Barber L.G. & Burgess K.E. (2010) Efficacy of maropitant in the prevention of delayed vomiting associated with administration of doxorubicin to dogs. Journal of Veterinary Internal Medicine 24, 1425–1427.

Rose W.C. & Schurig J.E. (1985) Preclinical antitumor and toxicologic profile of carboplatin. Cancer Treatment Reviews 12, 1–19.

Selmic L.E., Burton J.H., Thamm D.H., Withrow S.J. & Lana S.E. (2014) Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma. Journal of Veterinary Internal Medicine 28, 554–563.

Suda O. (2011) Measures for ageing of house-hold animals (dogs and cats) -how to let owners to accept the death of their animals. Journal of the Japanese Veterinary Medical Association 64, 22–26.
Tanaka N. (2011) Use of prescription records of medical products in secondary referral veterinary hospitals. In: *Use of Prescription Records of Medical Products in Secondary Referral Veterinary Hospitals* (ed K. Anpo), pp 33–39. Technical Information Institute Co. Ltd: Tokyo.

Tanaka N., Takizawa T., Miyamoto N., Funayama S., Tanaka R., Okano S. & Iwasaki T. (2017) Real world data of a veterinary teaching hospital in Japan: a pilot survey of prescribed medicines. *Veterinary Record Open* 4, e000218.

Wayne A., McCarthy R. & Lindenmayer J. (2011) Therapeutic antibiotic use patterns in dogs: observations from a veterinary teaching hospital. *Journal of Small Animal Practice* 52, 310–318.